Skip to main content

Day: February 26, 2024

Platinex Inc. Announces Name Change to PTX Metals Inc.

TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“Platinex” or the “Company”) is pleased to announce the completion of the name change to PTX Metals Inc. effective February 28, 2024. Management recommended the name change because ’Platinex‘ no longer accurately describes the Company’s expanded portfolio and focus on gold, copper-nickel-PGE projects. Trading will commence under the new name on Wednesday, February 28, 2024. The Company’s shares will continue to trade under the symbol PTX on the CSE, under the symbol PANXF on the OTCQB, and under 9PX on the Frankfurt Exchange. New ISIN/CUSIP numbers reflecting the name change are CA69380V1067/69380V106. Existing shareholders are able to deposit or trade their common shares in the former Company name and former CUSIP/ISIN. Effective...

Continue reading

Music Licensing, Inc. Reports Strong Fiscal Year 2023 Results

LogoLogoLogoLogoNAPLES, Fla., Feb. 26, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading player in the music licensing industry, today announced its annual results for the fiscal year ended December 31, 2023. The company has delivered robust performance, achieving significant milestones in revenue and profitability. Key financial highlights for the fiscal year 2023 include:Total Revenue: Music Licensing, Inc. reported total revenue of $1,052,274,588 USD, showcasing its ability to generate substantial income in a competitive market environment. Net Profit: The company achieved a net profit of $46,033,387 USD, demonstrating its efficiency in managing costs and maximizing profitability. Total Equity: Music Licensing, Inc. reported total equity of $49,580,139 USD, reflecting its solid financial...

Continue reading

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants...

Continue reading

Healthcare Triangle Empowers Healthcare Providers to Harness AI and LLMs for Groundbreaking Outcomes

Company’s latest initiative addresses growing demand for AI analytics to revolutionize patient care PLEASANTON, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Healthcare Triangle Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” HCTI” or the “Company”), a leader in transforming healthcare through technology, today unveiled an initiative aimed at enabling healthcare organizations to harness the full potential of their organic data through Artificial Intelligence (AI) and Large Language Models (LLMs). This initiative is set against the backdrop of a rapidly expanding AI market, with Grand View Research estimating the AI in healthcare market size was $22.45 billion in 2020, and is expected to expand at a compounded annual growth rate (CAGR) of 36.4% from 2024 to 2030. Healthcare Triangle’s latest offering is poised to empower healthcare...

Continue reading

Rodedawg Intl. Ind, Inc. (OTC: RWGI) Signs Exclusive Distribution Agreement with D9, LLC

Sales & Distribution of Cannabis Distillate Provider COSTA MESA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) —  Rodedawg International Industries, Inc. (OTC: RWGI) proudly announces the Company, through our wholly owned subsidiary, Parabola Mgmt. LLC, has signed an exclusive distribution and sales agreement with D9, LLC. Chris Swartz, CEO, states “D9 is one of the largest licensed cannabis distillate providers in California and are proud to inform our shareholders that after months of negotiations, we have signed the agreement for Parabola Mgmt., LLC to be the exclusive distributor. We expect that our cannabis distribution license in Coachella, CA will be one of our largest revenue centers for Rodedawg Shareholders. We passionately believe that with our recent completion of the distribution license application coupled with this exclusivity...

Continue reading

First Source Mortgage Fund Announces Estimated Top-Up Distribution for 2023 Distribution

TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) — First Source Mortgage Fund (“the Fund”) announces that it has an estimated Top-Up year-end distribution (the “Top-Up distribution”) of 109 bps per eligible Class F unit. The precise amount of the top-up distribution will be confirmed prior to the payment date. The top-up distribution recognizes that the (estimated) annual income generated in 2023 is expected to exceed the regular monthly distributions paid to unitholders. The Top-Up distribution is not indicative of future performance by the Fund. The total distribution per unit for Class F unitholders during 2023, inclusive of the estimate Top-Up distribution, was 9.47%/unit. This equates to a total annualized compounded return of 9.8% for 2023. David Mandel, CEO of First Source Mortgage Corporation, emphasizes the company’s successful...

Continue reading

Lincoln Educational Services Reports Results for Fourth Quarter and Full Year 2023

Strong Demand Driving Outlook for Continued Growth in 2024 Conference Call Today at 10 a.m. ET PARSIPPANY, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) today announced financial and operating results for the fourth quarter and full year ended December 31, 2023, as well as recent business developments. Fourth Quarter 2023 Financial Highlights*Revenue grew 13.6% to $102.5 million New student starts increased 16.0% Adjusted EBITDA of $15.7 million Adjusted net income of $10.0 million Earnings per share of $0.23 Cashflow from operations of $21.9 millionFull Year 2023 Financial and Operational Highlights*Revenue grew 10.3% to $376.6 million New student starts increased 11.4% Adjusted EBITDA of $26.5 million Adjusted net income of $14.8 million Earnings per share of $0.86 Total...

Continue reading

red violet to Announce Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

BOCA RATON, Fla., Feb. 26, 2024 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023 after the close of the U.S. financial markets on Thursday, March 7, 2024. The Company will host its earnings call on Thursday, March 7, 2024 at 4:30pm ET to discuss its quarterly and full year results and provide a business update. The participant registration and webcast information are listed below. The earnings call will be simultaneously webcast on the Investors section of the red violet website at www.redviolet.com. Please login at least 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be required. Please note participants must...

Continue reading

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

•   SUMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected by YE 2025 •   PEAK Phase 3 study of bezuclastinib + sunitinib in 2nd-line GIST patients on track to complete enrollment by end of 2024; topline results expected by YE 2025 •   APEX Part 2 registration-directed study of bezuclastinib in AdvSM patients on track to complete enrollment by end of 2024; topline results expected by mid-2025 •   $487 million in pro-forma cash sufficient to fund operations into 2027; includes net proceeds from oversubscribed $225 million February 2024 PIPE WALTHAM, Mass. and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing...

Continue reading

Save Foods Navigates Brazilian Regulation and Commences Commercial Activity Through Exclusive Local Distributor

Brazil ranked third globally in fruit export in 2023 Neve Yarak, Israel, Feb. 26, 2024 (GLOBE NEWSWIRE) — Save Foods, Inc. (NASDAQ: SVFD) (FSE:80W) (“Save Foods” or the “Company”), a pioneer Agri-Food Tech company offering sustainable solutions for agriculture and plant based food, announced today the commencement of commercial activity in Brazil. The Company’s entry into the Brazilian market was facilitated by the Company’s local exclusive distributor after confirming that Save Foods’ solutions comply with local regulations. With regulatory barriers unhindered, the Company’s distributor is set to start marketing an ordering process. According to Fresh Plaza, Brazil’s fruit exports witnessed a 6% rise in 2023, reaching a total of 1.06 million tons and generating revenue in excess of $1.2 billion, a substantial...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.